Copyright © 1993 by the European Society of Cardiology.
© 1993 The European Society of Cardiology
Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase
*Department of Cardiology Aberdeen, Scotland, U.K.
Department of Haematology Aberdeen, Scotland, U.K.
Department of Immunology Aberdeen, Scotland, U.K.
Received 14 April 1992; revised 8 July 1992; .
Correspondence: Dr Hai Shiang Lee, Department of Cardiology, Aberdeen Royal lnfirmary, Foresterhill, Aberdeen AB9 2ZB, Scotland, U K
Abstract
Streptokinase and anistreplase are antigenic and their administration often leads to antibody formation. These can cause allergic reactions and/or neutralization of streptokinase with resulting suboptimal treatment. Currently, streptokinase re-administration is considered appropriate for up to 5 days and from 1 year after a previous dose. Antistreptokinase antibody and neutralization titres (NT) were measured in three groups of patients to determine if this practice is appropriate: 1. (early)—36 patients whose titres were measured for at least 5 days after thrombolysis; 2. (late)—57 patients who received thrombolysis 12–54 months previously; 3. (controls)—182 consecutive suspected myocardial infarction patients (without previous exposure to thrombolysis).
Results were as follows (mean±SEM): 1. (early)—the antibody and/or NT were raised by day 4 in 19.4% of the patients. One patient could have neutralized 1.97 million units (MU) of streptokinase by day 4. (Day 4—antibody 1:39±11, NT 0.19±0.05 MU; day 5–1:136±41 and NT 0.7±0.43 MU respectively.) 2. (late)—23 patients (40%) had either antibody titres 
1:160 and/or NT> 1.5 MU. (12–23 months—antibody 1:243±43, NT 0.63±0.15 MU; 24–35 months—1:98±31 and 0.69±0.22 MU; 36–54 months—1:87±14 and 0.54±0.12 MU.) All titres were significantly higher than the controls (antibody 1:25±3. NT 0.14±0.01 MU, P<0.01).
After streptokinase or antistreplase, antibodies are raised from 4 days to at least 54 months. It would seem prudent to avoid their re-administration during this time interval.
Key Words: Thrombolysis • myocardial infarction • antibody • neutralization titres
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Cardillo, F. Carleo, L. Carbone, M. Di Martino, L. Salvadori, L. Petrella, and M. Martelli Chronic postpneumonic pleural empyema: comparative merits of thoracoscopic versus open decortication Eur. J. Cardiothorac. Surg., November 1, 2009; 36(5): 914 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-P. Luh, M.-C. Chou, L.-S. Wang, J.-Y. Chen, and T.-P. Tsai Video-Assisted Thoracoscopic Surgery in the Treatment of Complicated Parapneumonic Effusions or Empyemas: Outcome of 234 Patients Chest, April 1, 2005; 127(4): 1427 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C W H Davies, F V Gleeson, and R J O Davies BTS guidelines for the management of pleural infection Thorax, May 1, 2003; 58(90002): ii18 - 28. [Full Text]
|
|
|
|
|
|
T. Laisaar and T. Pullerits Effect of Intrapleural Streptokinase Administration on Antistreptokinase Antibody Level in Patients With Loculated Pleural Effusions Chest, February 1, 2003; 123(2): 432 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]
|
|
|
|
 |
|
 J. P. McRedmond, P. Harriott, B. Walker, and D. J. Fitzgerald Streptokinase-induced platelet activation involves antistreptokinase antibodies and cleavage of protease-activated receptor-1 Blood, February 15, 2000; 95(4): 1301 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Jennings Antibodies to streptokinase BMJ, February 17, 1996; 312(7028): 393 - 394. [Full Text]
|
|